The cyclooxygenase-2 inhibitor celecoxib effectively suppresses the development of non-melanoma skin cancers: results of a phase II/III clinical trial

被引：0
|
作者：
Elmets, C. A. [1 ]
Viner, J. L. [7 ]
Pentland, A. P. [9 ]
Cantrell, W. [1 ]
Bailey, H. [2 ]
Kang, S. [3 ]
Linden, K. G. [4 ]
Heffernan, M. [5 ]
Madeleine, D. [6 ]
Elewski, B. [1 ]
Umar, A. [7 ]
Lin, H. [1 ]
Bell, W. [1 ]
Gordon, G. [8 ]
机构：
[1] Univ Alabama, Birmingham, AL USA
[2] Univ Wisconsin, Madison, WI USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
[4] Univ Calif Irvine, Irvine, CA USA
[5] Washington Univ, St Louis, MO USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] NCI, Bethesda, MD 20892 USA
[8] GD Searle Inc, Skokie, IL USA
[9] Univ Rochester, Rochester, NY USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2009年 / 129卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
325
引用
收藏
页码：S55 / S55
页数：1
相关论文
共 50 条
  • [41] Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial
    Luke, Jason J.
    Zha, Yuanyuan
    Matijevich, Karen
    Gajewski, Thomas F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
  • [42] Bevacizumab plus erlotinib maintenance versus observation in advanced biliary tract cancers: Results from the phase II component of a prospective integrated phase II-phase III parallel design superiority clinical trial (BEER-BTC study)
    Ramaswamy, A.
    Ostwal, V. S.
    Bhargava, P. G.
    Srinivas, S.
    Kapoor, A.
    Goel, M.
    Patkar, S.
    Gupta, A.
    Sansar, B.
    Kapu, V.
    Mishra, B.
    Sharma, A.
    Rai, R. K.
    Gupta, P.
    Mandavkar, S.
    Parulekar, M.
    Chaugule, D.
    Aier, N.
    Patil, R.
    Nashikkar, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S217 - S217
  • [43] Phase 2 Clinical Trial Results for Bitopertin, an Oral Glycine Transporter 1 Inhibitor, in Patients with Non-Transfusion Dependent Beta-Thalassemia
    Taher, Ali
    Viprakasit, Vip
    Cappellini, Maria Domenica
    Kraus, Dominik
    Cech, Patrick
    Dietmar, Volz
    Winter, Erica
    Mazer, Norman Alan
    Nave, Stephane
    Dukart, Juergen
    Stark, Franziska Schaedeli
    Koerner, Annette
    Khwaja, Omar
    Hermosilla, Ricardo
    BLOOD, 2018, 132
  • [44] Results of Phase 1b trial of the Indoleamine 2,3-dioxygenase (IDO) Pathway Inhibitor Indoximod plus Ipilimumab for the treatment of unresectable stage III or IV melanoma
    Zakharia, Y.
    Drabick, J.
    Khleif, S.
    Munn, D.
    Link, C.
    Vahanian, N.
    Kennedy, E.
    Rixe, O.
    Milhem, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S108 - S108
  • [45] Results of a phase II trial with cystemustine at 90 mg/m2 as a first- or second-line treatment in advanced malignant melanoma:: a trial of the EORTC Clinical Studies Group
    Cure, H
    Souteyrand, P
    Ouabdesselam, R
    Roche, H
    Ravaud, A
    D'incan, M
    Viens, P
    Fargeot, P
    Lentz, MA
    Fumoleau, P
    Hanauske, A
    Chollet, P
    MELANOMA RESEARCH, 1999, 9 (06) : 607 - 610
  • [46] Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alfa-2b in advanced melanoma outpatients: Results from an Italian Multicenter phase III Randomized Clinical Trial
    Ridolfi, R
    Chiarion-Sileni, V
    Guido, M
    Romanini, A
    Labianca, R
    Freschi, A
    Lo Re, G
    Nortilli, R
    Brugnara, S
    Vitali, P
    Nanni, O
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) : 1600 - 1607
  • [47] Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma
    Ribas, A.
    Antonia, S.
    Sosman, J.
    Kirkwood, J. M.
    Redman, B.
    Gajewski, T. F.
    Pavlov, D.
    Bulanhagui, C.
    Gomez-Navarro, J.
    Camacho, L. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [48] MKC-1 a novel cell cycle inhibitor: preclinical studies to support Phase 2 clinical trial evaluations in pancreatic and non-small cell lung cancers (NSCLC)
    LaVallee, T.
    Brokx, R.
    Burke, P.
    Fletcher, G.
    Plum, S.
    Fogler, W.
    Treston, A.
    Sidor, C.
    Bray, M.
    EJC SUPPLEMENTS, 2006, 4 (12): : 134 - 134
  • [49] ß-2 adrenergic receptor (AR): Another immune checkpoint (IC)" A phase II clinical trial of propranolol (P) with pembrolizumab (Pem) in patients with unresectable stage III and stage IV melanoma
    Switzer, Benjamin
    Pandey, Manu R.
    Valentine, Alexandra
    Witkiewicz, Agnieszka
    Knudsen, Erik
    Attwood, Kristopher
    Tario, Joseph
    Funchain, Pauline
    Drabick, Joseph J.
    Mohammadpour, Hemn
    Ernstoff, Marc S.
    Puzanov, Igor
    Repasky, Elizabeth A.
    Gandhi, Shipra
    CANCER RESEARCH, 2022, 82 (12)
  • [50] Aflibercept-LV5FU2 as first-line treatment of non-resectable metastatic colorectal cancers: Results of the FOLFA randomized phase II trial.
    Legoux, Jean-Louis
    Faroux, Roger
    Barriere, Nicolas
    Le Malicot, Karine
    Tougeron, David
    Lorgis, Veronique
    Guerin-Meyer, Veronique
    Bourgeois, Vincent
    Malka, David
    Aparicio, Thomas
    Baconnier, Mathieu
    Ly, Valerie Lebrun
    Egreteau, Joelle
    Akouz, Faiza Khemissa
    Lepage, Come
    Boige, Valerie
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345